Currently available molecular signatures assess the risk of recurrence and the benefit of chemotherapy; however, these tests may have large intermediate risk groups, limiting their usefulness. We describe a novel 5-gene signature that is a robust prognostic assay that performed similarly to currently available signatures in concordance analyses. However, it identified significantly fewer patients as intermediate risk and more as low risk than currently available assays. Introduction: Early stage estrogen receptor (ER)-positive breast cancer may be treated with chemotherapy in addition to hormone therapy. Currently available molecular signatures assess the risk of recurrence and the benefit of chemotherapy; however, these tests may have large intermediate risk groups, limiting their usefulness. Methods: The EarlyR prognostic score was developed using integrative analysis of microarray data sets and formalin-fixed, paraffinembeddedebased quantitative real-time PCR assay and validated in Affymetrix data sets and METABRIC cohort using Cox proportional hazards models and Kaplan-Meier survival analysis. Concordance index was used to measure the probability of prognostic score agreement with outcome. Results: The EarlyR score and categorical risk strata (EarlyRLow, EarlyR-Int, EarlyR-High) derived from expression of ESPL1, MKI67, SPAG5, PLK1 and PGR was prognostic of 8-year distant recurrence-free interval in Affymetrix (categorical P ¼ 3.5 Â 10 À14 ; continuous P ¼ 8.8 Â 10 À15 ) and METABRIC (categorical P < 2.2 Â 10 À16 ; continuous P < 10 À16 ) data sets of ER þ breast cancer. Similar results were observed for the breast cancerefree interval end point. At most 13% of patients were intermediate risk and at least 66% patients were low risk in both ER þ cohorts. The EarlyR score was significantly prognostic (distant recurrence-free interval; P < .001) in both lymph nodeenegative and lymph nodeepositive patients and was independent from clinical factors. EarlyR and surrogates of current molecular signatures were comparable in prognostic significance by concordance index. Conclusion: The 5-gene EarlyR score is a robust prognostic assay that identified significantly fewer patients as intermediate risk and more as low risk than currently available assays. Further validation of the assay in clinical trialederived cohorts is ongoing.
Introduction
Classification and management of a disease significantly reflects understanding of the disease condition. Until recently, breast cancer was believed to be a single disease that was treated by surgical excision followed by chemotherapy, with the addition of tamoxifen for estrogen receptor (ER)-positive disease. Molecular analysis of breast cancers using gene expression microarrays resulted in the recognition of breast cancer as a heterogeneous disease in which different subtypes respond to distinct therapeutic regimens. 1, 2 In recent years, numerous genomic assays, including Oncotype DX, therapy alone for low-risk patients (RS 18) , and hormone therapy and adjuvant chemotherapy for high-risk patients (RS ! 31). Physicians may alternatively use prognostic information from other molecular signatures to guide treatment. Multiple studies have reported a reduction in the proportion of ER þ patients receiving chemotherapy concurrent with adoption of Oncotype DX. 10, 11 The impact of such a genomic assay on treatment decisions depends in part on the proportions of patients with disease classified as low risk, high risk, or intermediate risk. The 15, 16 ). To build evidence of the clinical utility of the test, we converted it to a proof-ofprinciple quantitative real-time PCR (qPCR)-based assay for formalin-fixed, paraffin-embedded (FFPE) tissue.
Methods

Microarray Data Sets
The Affymetrix training set used in this study was obtained from the LN À samples in GSE3494 17 and GSE7390 18 (Gene Expression Omnibus; http://www.ncbi.nlm.nih.gov). The validation set was derived from patients from the following data sets: GSE12093, 19 GSE6532, 20 GSE2034, 21 GSE11121, 22 and GSE17705. 23 The CEL files from all series were normalized together and expression values computed with the GCRMA (GC Robust Multiarray Average) package. 24 Batch effects were eliminated with the ComBat tools. 25 The patient characteristics of the Affymetrix (training and validation) and METABRIC cohorts are described in Supplemental Table 1 in the online version. None of the patients in the Affymetrix cohorts had received chemotherapy, and 46% had received hormone therapy. Patients in METABRIC cohort 14 were treated with hormone therapy and/or chemotherapy as directed by the treating physician. In contrast to current practice, hormone therapy was predominately prescribed only for patients with positive LNs or large tumors (> 2 cm); only 54% of LN À patients received hormone therapy. A tumor in METABRIC cohort was considered HER2 þ if there was gain in the number of copies of ERBB2 as assessed using microarray-based copy number analysis. 14 The prognostic significance of EarlyR was studied as per the STEEP guidelines. 26 Distant recurrence-free interval (DRFI) was defined as the time from surgery to recurrent distant metastatic breast cancer; breast cancerefree interval was defined as the time from surgery to recurrent distant metastatic breast cancer or locoregional invasive ipsilateral breast cancer. Data for both breast cancerefree interval and DRFI were obtained for patients in the METABRIC cohort (unpublished data). In Affymetrix cohorts, the end points were described as distant metastasis-free survival. It is unlikely that differences between study-specific end points and DRFI would result in significant changes in the number of events in these data sets. Prognostic significance with respect to DRFI and breast cancerefree interval was assessed up to 8 years after diagnosis. The threshold of 8 years was chosen on the basis of a prior publication from the Cuzick group showing that the prognostic utility of current genomic signatures for ER þ breast cancer deteriorates after 8 years. 27 
Sample Selection and Preparation
The institutional review board of Indiana University approved the study. An informed consent waiver was obtained, and only deidentified data were used in the analyses.
Archival FFPE tumor blocks were chosen from 72 patients with breast cancer at the Indiana University Simon Cancer Center based on their Oncotype DX RS. Initial real-time qPCR analysis was conducted using 10 samples of ER þ breast cancers. This was followed by qPCR analysis using customized arrays of 23 cases with high RS, 26 cases with intermediate RS, and 23 cases with low RS. Demographic and clinical characteristics of the patients were acquired from medical charts (Supplemental Table 2 in the online version). The cases were equally divided into training and validation sets, each of 36 cases. The distribution of RS in the training set was shown to be significantly equivalent to the distribution of RS in the validation set using the Kolmogorov-Smirnoff test (P ¼ .88).
RNA was extracted from 10 mm thick sections of archival paraffin blocks using RecoverAll Total Nucleic Acid Isolation Kit (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. The quality of RNA was assessed using the Nanodrop ND-1000 spectrophotometer (ThermoScientific, Wilmington, DE). Total RNAs were reverse transcribed using the High Capacity cDNA Reverse Transcription kit (Life Technologies) according the manufacturer's instructions.
Selection of TaqMan qPCR Assays
Specific target sequences for each probe from the Human Genome U133A 2.0 Array were obtained using the NetAffx Analysis Center (http://www.affymetrix.com/analysis/index.affx). Target sequences were aligned to the appropriate messenger RNA reference sequence (REFSEQ) accession number using National Center for Biotechnology Information (NCBI) BLAST (Basic Local Alignment Search Tool) (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and accessed the consensus sequence through the NCBI Entrez nucleotide database.
Using the UMapIt mapping tool of Applied Biosystems (ABI, Foster City, CA), the Affymetrix probe IDs were mapped to TaqMan assays specific to each sequence. TaqMan assays, where necessary custom designed using Primer Express (ABI), were tested for the amplification efficiency on the basis of the ABI-defined criteria. Control RNA (Universal Human Reference RNA; Stratagene, San Diego, CA) and FFPE samples were used to test the efficiency of the probes. On the basis of the observed efficiency, probes were selected for custom array microfluidic cards (TaqMan assays; Supplemental Table 3 in the online version).
qPCR Analysis Using Custom Arrays
TaqMan reactions were performed in triplicate using custom array microfluidic cards preloaded with TaqMan Gene Expression
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Robust Gene Expression Signature Assays containing 17 genes (12 discriminant genes and 5 reference genes) on an ABI Prism 7900HT Fast Real-Time platform according to the manufacturer's instructions (Supplemental Table 3 in the online version). ACTB, TFRC, GUS, RPLPO, and GAPDH were used as endogenous reference controls for normalization. Delta threshold cycle values for each of the 12 genes of interest were normalized using these endogenous controls according to the method of ABI DataAssist v3.0 software.
Construction of Genomic Signature From Gene Expression Measurements
The methodology for construction of a genomic signature is described in detail in the Supplemental Methods in the online version.
Statistical Analyses
All statistical analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org/). Mixture models were fit using the package mclust, 28, 29 and survival analysis was performed with the package survival. The significance of a Cox proportional hazard (CPH) model was assessed with the P value of the log-rank score test. The significance of a multivariate CPH over a CPH using a subset of the variables was measured with a chi-square test of the log likelihoods. The proportional hazard condition was tested with the cox.zph function. The prognostic significance of genomic signatures was compared using the concordance index. 30, 31 The concordance index estimates the probability that, for a random pair of patients, the patient with earlier recurrence has a higher score than the patients with either later or no recurrence. The concordance index is a number between 0 and 1 and is defined more formally in the Supplemental Methods in the online version. A concordance index greater than 0.5 indicates that the prognostic score is more significant than random chance. A confidence interval for concordance index was computed by resampling. A function from the survcomp package was used to compute concordance index.
Computation of Alternative Genomic Signatures
To compare the prognostic significance of EarlyR with that of Oncotype DX, Mammaprint, and ROR score, we computed surrogates of these signatures in METABRIC using the Bioconductor genefu package. 32 To compute Oncotype DX, we selected probes in the IlluminaHuman-v3 platform (Illumina, San Diego, CA) representing the 16 target genes in the panel; 3 for genes represented by multiple probes, we selected the probe with the highest variance in the ER þ METABRIC cohort, the recommended method in genefu.
Probes representing all 16 target genes were identified, and the RS was computed using the package's function for that purpose. Mammaprint was derived from a 70-gene signature, 4 referred to as GENE70 in genefu. GENE70 was originally computed using 70 array probes from the Agilent Hu25K array platform (Agilent Technologies, Santa Clara, CA), of which 56 were associated with 52 unique Entrez IDs. For these 52 Entrez IDs, Illumina probes were selected that had the highest variance in METABRIC. From these probes, and the appropriate genefu function, a continuous GENE70 score was computed. The GENE70 stratification into low-risk and high-risk groups was computed using a GENE70 score threshold that produced a low-risk group containing 50% of the ER þ , LN À METABRIC cohort.
The ROR score 6 was computed in METABRIC using the appropriate genefu function with the default arguments. The ROR stratification was created with the same percentages in low-, intermediate-, and high-risk groups for ER þ METABRIC as for trans-ATAC, 33 specifically, 55%, 25%, and 20%, respectively.
Results
Discovery of EarlyR
To identify the gene signature, an integrative approach consisting of analysis of in silico data and FFPE samples was used (Supplemental Figure 1 in the online version). This was undertaken to ensure stability of the probes in fresh and frozen tissue and across multiple analytical platforms. Prior analysis of GSE4922 (UPPS), GSE6532 (OXFD, GUYT), GSE7390 (TRANSBIG), GSE9195 (GUYT2), and GSE11121 (MZ) 13 led to the identification of a set of 12 genes (ESPL1, CDC45L, PLK1, CENPA, MKI67, SPAG5, CDT1, PGR, CXCL9, PHLPP1, CDC6, PRPF4) that provided prognostic information in these ER þ breast cancer samples. To determine the feasibility of using these probes for a prognostic signature with FFPE tissue, we performed a qPCR analysis of these 12 genes in a training set of 36 ER þ breast cancer FFPE samples with known Oncotype DX RS (Supplemental Table 2 in the online version). For each of the 12 target genes on the qPCR array, risk scores were derived using the DÀCT values from the training set of 36 samples (Supplemental Methods). The 9 genes whose risk scores were significantly predictive of TAILORx risk group (P value of the linear model < .05) were considered for further gene signature development. The 9 genes (ESPL1, CDC45L, PLK1, CENPA, MKI67, SPAG5, CDT1, PGR, CXCL9) identified by the above method were further analyzed for inclusion in a multigene signature in the Affymetrix training data set of 266 ER þ , LN À breast cancers obtained from GSE3494 17 and GSE7390. 18 The incremental impact of addition of each gene to the prognostic score was analyzed starting with the most prognostic gene, ESPL1. Next, the top 2 genes (ESPL1 and SPAG5) were combined to derive a 2-gene signature score (Supplemental Methods in the online version). This process was continued until the multigene score with maximally significant results was obtained (Supplemental Methods in the online version). This signature, EarlyR score, uses the genes ESPL1, MKI67, SPAG5, PLK1, and PGR. Specifically, the EarlyR score was computed in the Affymetrix-based cohorts using a gene signature derived from the expression of the following 5 probes: 204817_at (ESPL1), 212022_s_at (MKI67), 203145_at (SPAG5), 202240_at (PLK1), and 208305_at (PGR).
Concordance of EarlyR and RS in FFPE Samples
To reconfirm the ability of EarlyR to assess risk in FFPE tissues, we showed that the Oncotype DX RS is linearly dependent on the Table 2 in the online version). Samples were further separated into risk groups with respect to RS using the Oncotype DX thresholds 3 and the TAILORx thresholds. 34 We found a significant concordance between EarlyR risk strata and Oncotype DX risk strata (P ¼ .004) and TAILORx risk strata (P ¼ .002). This confirms the feasibility of using EarlyR for the analysis of FFPE samples.
Validation of EarlyR in Affymetrix and METABRIC Cohorts
The EarlyR score and the EarlyR strata, EarlyR-Low (EarlyR 25), EarlyR-Int (25 < EarlyR 75), and EarlyR-High (75 < EarlyR) were computed from the score values in all validation cohorts (GSE12093, 19 GSE6532, 20 GSE2034, 21 GSE11121, 22 GSE17705, 23 and METABRIC). This computation was performed in a manner blinded to all clinical features of the samples (Supplemental Methods in the online version). EarlyR score classified a large majority of samples as either lowrisk or high-risk in the Affymetrix ( Figure 1A ) and METABRIC ( Figure 1B ) validation cohorts. Moreover, the percentage of samples in each stratum was comparable across subgroups defined by clinical traits (Supplemental Table 4 Figure 3A ,B, Supplemental Figure 4A ,B in the online version). Also, among those ER þ patients with LN À disease who were treated with hormone therapy, EarlyR stratification and continuous score were both prognostic in the Affymetrix validation cohort and METABRIC (Table 1 , Figure 3C ,D, Supplemental Figure 4C ,D in the online version Figure 4D ).
EarlyR Prognostic Significance in Multivariate Analysis Including Clinicopathologic Variables
The independence of EarlyR from clinicopathologic variables was assessed using multivariate Cox models in accordance with the REMARK recommendations. 35 Adding EarlyR to each of LN status, tumor size (binary and continuous), patient age (binary), and tumor grade significantly increased the prognostic significance of the clinical variable (Supplemental Table 5 in the online version) in METABRIC. In a Cox model including LN, binary tumor size, binary age and grade, the addition of EarlyR significantly improved on the prognostic significance of the clinically based model (P ¼ 1.1 Â 10 À12 for the chi-square statistic of the log likelihoods). This provided strong evidence that EarlyR offers prognostic information that cannot be derived from clinicopathologic variables.
In multivariate Cox models (using 8-year DRFI) including stratified EarlyR and each of tumor size, age, and tumor grade, Robust Gene Expression Signature 
Prognostic Significance of EarlyR Was Superior or Comparable to Other Genomic Assays
Surrogates for RS, 3 GENE70 (a precursor of Mammaprint), 4, 5 and ROR, 6 as well as stratified versions, were computed for the METABRIC cohort using the genefu R package. 32 The concordance index 30, 31 was used to compare the prognostic significance of these tests as continuous scores, as has been previously done for prognostic assays. 16 These comparisons (Supplemental Figure 5 in the online version) showed that the concordance index was highest for EarlyR followed by RS, GENE70, and ROR scores, in that order, although this difference was not statistically significant by the 95% confidence intervals. This established that EarlyR was at least as prognostic as surrogates of these other signatures. Expected survival probabilities (8-year DRFI) for stratified versions of EarlyR and the RS, GENE70, and ROR were computed in the ER þ , LN À , HER2 À METABRIC cohort (Supplemental Table 6 in the online version). The expected survival probability in EarlyR-Low was nearly the same as for the other signatures, although EarlyR-Low contained 72% of samples; the low-risk groups for RS, GENE70, and ROR were 55%, 55%, and 62%, respectively.
Discussion
The decision to use adjuvant chemotherapy to treat early stage breast cancer must balance the reduced risk of metastasis with chemotherapy's toxic effects. Increasingly, tests that analyze gene expression patterns in primary tumors are being used to guide this decision. Herein, we have developed an assay wherein the EarlyR score (0-100) is defined by combining the risk scores of the 5 panel genes using a nonlinear formula. The computation of the EarlyR score, and the resulting stratification into risk groups, is intended to offer the convenience of discrete classification (EarlyR-High or 12, 16, 36 In spite of the larger low risk stratum for EarlyR, by using surrogates of RS, Mammaprint, and ROR in METABRIC, we showed that EarlyR is at least as significant as a prognostic tool using concordance index and expected survival. EarlyR-Int consists of samples in which EarlyR score is rising sharply from the low-risk group to the high-risk group; ie, these are samples that straddle the boundary between good and poor prognoses. In multiple Kaplan-Meier analyses, we found that the expected survival probability for EarlyR-Int was comparable to that of EarlyR-High (Figures 2 and 3) . Further studies in well-annotated clinical trial cohorts will determine the need for this intermediaterisk category.
In the ER þ , LN À , HER2 À METABRIC samples, the 8-year distant recurrence-free survival estimate for the EarlyR low risk stratum was 88%. This estimated survival percentage was markedly lower than that computed for RS and ROR in transATAC 16 or for Mammaprint in the MINDACT trial. 15 However, the low-risk strata for surrogates of these other signatures in the same subset of METABRIC are between 87% and 89% (Supplemental Table 6 in the online version). This is likely because only 52% of these patients received hormone therapy, and 54% of them had tumors > 
Figure 4 Kaplan-Meier Survival Curves With Respect to BCFI Plotted for EarlyR Risk Strata for METABRIC Samples. (A) ER
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2 cm in diameter. In contrast, in MINDACT, all ER þ patients were recommended for hormone therapy, and only 28% of tumors (including both LN À and LN þ ) were > 2 cm.
Tumor size has been found to be significantly prognostic independent of ROR, 6 RS, 37 and EndoPredict. 38 The commercial Prosigna score combines ROR with tumor size to form a single score, and EPclin combines EndoPredict and tumor size. We found that tumor size was also significantly prognostic independent of EarlyR in the ER þ , LN À METABRIC cohort. To elucidate the combined prognostic significance of EarlyR and tumor size, we reported the prognostic significance of EarlyR separately in tumors 2 cm and tumors > 2 cm. We think that conflating size and a genomic score into a single score confuses the independent effects of the 2 risk factors. Each gene in the EarlyR panel, ESPL1, MKI67, SPAG5, PLK1, and PGR, plays a role in multiple processes related to ER þ breast cancer progression and treatment response. ESPL1, which is critical for the timely separation of sister chromatids during anaphase, has been found to be disproportionately elevated in luminal B tumors and has also been found to be a risk factor independent of PAM50, RS, Mammaprint, and EndoPredict. 39 MKI67 is a well-studied biomarker for proliferation. Elevated expression of SPAG5, which is associated with the mitotic spindle apparatus, is predictive of sensitivity to cytotoxic chemotherapy in breast cancer. 40, 41 PLK1 is known to promote hormone-independent ER transcription and growth, 42 as well as being associated with mutations of TP53. 43 The role of the hormone receptor PGR in progression of breast cancer is well established. Prognostic signatures for ER þ breast cancer, including EarlyR, were developed to assist physicians in selecting patients for hormone therapy alone or combined with systemic chemotherapy. 44 Studies are planned to build evidence that patients identified as high risk by EarlyR are good candidates for chemotherapy, while those in EarlyR-Low are unlikely to benefit from chemotherapy.
There are a number of limitations of the current study. The major limitation is that all of the analyses were performed in a retrospective manner using in silico data obtained from several studies with only 2775 samples. These studies had variable methods of preanalytical tissue preparation, analytical techniques (U133A and IlluminaHuman-v3) and statistical analytic methods. Moreover, the samples were from patients not treated under current standards for ER þ breast cancer in that many did not receive hormone therapy or chemotherapy. However, despite these, the EarlyR score showed remarkable stability in predicting outcomes. Another important issue is the small number of FFPE samples used in the study. This analysis was meant to provide a proof of principle for an assay to execute EarlyR testing with qPCR using FFPE tissues. Additional studies are planned using clinical trial samples to validate the results of the studies presented herein.
Conclusion
The EarlyR assay is a risk score that classified at least 85% of ER When the mixture model M defines more than 2 intervals, it defines more than one possible threshold between high and low expression values. In this case, there are several possible risk scores for this gene. In defining a prognostic signature using these methods, the discovery process will select the risk score that results in the most significant signature. In the discovery process, if the model M for a specific gene has only one component, then that gene will be eliminated from consideration for the panel.
It bears emphasizing that the gene risk score is derived from fitting a model to the gene's expression values. There is no algebraic formula for computing the risk score. The computer program for executing the model fit is proprietary.
Multistate Gene Signatures
Given panel genes g 1 ,.,g n for a multistate gene signature, derived through the discovery process given below, and a cohort of patient samples, C, for which expression values of g 1 ,.,g n have been assayed, the multistate gene signature score is computed as follows.
1. For each panel gene g i , let r i be the gene risk score for g i in C. 2. The signature score S is 1 minus the product of all numbers of the form (1 À r i r j ), as (i,j) range over all possible distinct pairs from 1 to n. For convenience, S is scaled to 0-100. (If we interpret r i as the probability that a sample is in a highrisk state due to gene g i , then S is the probability that some pair of panel genes are in high-risk states.) 3. Given the continuous score S, discrete risk strata for the signature are defined as low risk (S 25), intermediate risk (25 < S 75), and high risk (75 < S).
Going forward, it is important to bear in mind the following:
The computation of the score S in a cohort of patient samples is independent of the technology used to measure gene expression and all clinical data. The signature risk strata are computed directly from the score values and thus are also independent of clinical data.
Discovery of Multistate Signature
To discover a multistate gene signature, a training cohort of samples with whole-genome expression data is selected. From the expression values for all genes assayed, all possible gene risk scores are computed and are individually evaluated for prognostic significance using the score statistic of a Cox proportional hazards model. Ranking these by individual significance, sets of genes are combined as possible panels and the resulting signatures computed. A set of panel genes is selected whose signature is maximally prognostic, as computed for Cox proportional hazards models. More specifically, if P i is the signature produced with the i highest ranked genes, then we select as the signature the minimal i such that the Cox proportional hazards model with variables P i and P iþ1 is not statistically more significant than that with the variable P i , compared using log likelihoods.
Computation of Multistate Gene Signature Score for Samples Not in Training Cohort
In the training cohort, gene risk scores are computed using the model fitting process described above. To compute the signature score for a new sample, the expression values for the panel genes are assayed and compared to the expression values in a reference set of samples (such as the training cohort). A lookup table is used to estimate the risk score values for each of the panel genes. Subsequently, the signature score values are computed as described above.
Concordance Index
The concordance index for a continuous score S in a set of samples X with survival data Event and Time, is computed as follows. A pair, i, j, from X is called evaluable if at least one incurred an event, and if only one incurs an event (say i), then the censoring time of j is later than the event time for i. For each evaluable pair, i and j compute a number c(i,j) to be 1 if i relapses before the relapse or follow-up time of j and S(i) < S(j); c(i,j) is also 1 if the preceding clause is true after switching i and j. The concordance index for S in X is then the mean of the numbers c(i,j) over all evaluable pairs. If S is a stratification rather than a continuous score, then the formula is adjusted. 
